Compass Pathways Plans Slow COMP360 Rollout, As Phase 3 Response Rates Meet REMS Reality

Compass Pathways is nearing the end of its regulatory filing for COMP360, its synthetic psilocybin treatment for treatment-resistant depression, but the company’s latest public messaging was less about speed than about launch control. Speaking at the STAT Summit in Boston, CEO Kabir Nath said Compass will “go slow before we go fast,” arguing that poor early patient or provider experiences could hurt the broader psychedelics sector.

The company is preparing to complete a rolling FDA submission this quarter and is aiming to launch early next year if the treatment is approved. Nath said Compass expects COMP360 to be subject to an FDA risk evaluation and mitigation strategy, or REMS, and is investing in provider training ahead of a potential launch.

That posture reflects a basic commercial reality for psychedelic therapies: approval would only be the first gate. COMP360 is not being framed as a conventional pill but as a supervised intervention that, in Compass’s trials, involves a roughly six-hour session. That means uptake will depend not just on the drug’s effect size, but on whether clinics can deliver the treatment consistently and whether payers will reimburse the monitoring time around it.

The clinical case and its constraints

Nath said that unlike conventional antidepressants, which can take weeks to work and require daily dosing, psilocybin has shown potential for rapid and lasting improvement after a small number of administrations. In Compass’s Phase 3 trials, roughly a quarter of patients had a clinically meaningful response after a single administration of COMP360. That rose to about 40% after a second dose three weeks later.

He also said longer-term data suggest that patients who respond can see benefits lasting as long as a year after two or three administrations. For treatment-resistant depression, that durability claim is a major part of the value proposition, because it points to a model built around episodic intervention rather than continuous use.

But the discussion also highlighted why regulators, clinicians, and payers are likely to scrutinize the evidence carefully. Steven Hyman, a Harvard University professor and former director of the National Institute of Mental Health, said psychedelic trials face a basic challenge in proving efficacy because patients often know they received the active drug due to its distinctive effects, which can compromise blinding. He cited this as one concern in the rejection of an MDMA-based therapy from Lykos Therapeutics by the FDA in 2024.

Hyman also pointed to a more fundamental unanswered question: whether the psychedelic experience itself is necessary for the antidepressant effect. Some companies are trying to develop compounds that preserve antidepressant benefits without hallucinations or other intense subjective effects. If that separation proves possible, the treatment model could shift dramatically toward simpler prescribing and at-home use. For now, he said, “we don’t know.”

Commercial execution is the real test

Compass has deliberately separated psychotherapy from its clinical trials. Nath said the company’s responsibility is to develop a drug, not prescribe how physicians should provide psychological care, and he noted that an analysis of recorded treatment sessions found roughly 80% of the time was spent in silence. Hyman said psychotherapy after the experience could still help patients process emotions, memories, and other effects, but emphasized that the field has not yet determined how much benefit comes from pharmacology versus the experience around it.

That uncertainty is commercially important. If patient outcomes depend heavily on support models that vary by site, scaling a launch becomes harder. If outcomes depend mostly on the drug, commercialization becomes more standardized. Compass is effectively moving forward before that debate is fully settled.

On access, Nath declined to commit to a specific pricing benchmark relative to Johnson & Johnson’s Spravato, though he said Spravato is a reference point. He added that Compass has spent years working on reimbursement mechanisms for the required monitoring and is engaging with commercial insurers and the Centers for Medicare and Medicaid Services on coverage.

The signal from Compass is that the first psilocybin launch, if it happens, will be judged as a care-delivery model as much as a drug approval. A cautious rollout is not just brand management. It is an attempt to keep the product’s logistical burden, payer negotiations, and unresolved scientific debates from overwhelming the initial promise shown in Phase 3.